Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,681
Out of 5,099 analysts
8
Total ratings
11.11%
Success rate
-44.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.50 | +1,572.24% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $2.61 | +283.88% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $3.28 | +144.27% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $36.85 | +127.95% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $8.39 | +376.76% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $7.64 | +44.07% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $1.74 | +1,106.90% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $12.80 | +6,931.25% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.50
Upside: +1,572.24%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $2.61
Upside: +283.88%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $3.28
Upside: +144.27%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $36.85
Upside: +127.95%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $8.39
Upside: +376.76%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $7.64
Upside: +44.07%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $1.74
Upside: +1,106.90%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $12.80
Upside: +6,931.25%